HYGEIA Hospital
ΛΗΤΩ Μαιευτικό, Γυναικολογικό & Χειρουργικό Κέντρο
HYGEIA Hospital Tirana
Y-Logimed Α.Ε.
AlfaLab | Kέντρο Μοριακής Βιολογίας & Κυτταρογενετικής
Beatific® | Super-effective Anti-aging Skincare for Face - Eyes - Body

3rd Internal Medicine - Oncology Clinic

The 3rd Department of Medical Oncology is staffed by specialized physicians who provide comprehensive care and support to the oncology patient. Our team consists of 3 Oncologists who have studied abroad and have extensive clinical experience, in addition to two Internists. This primary team is also assisted by one junior doctor, three nurses, and administrative staff who contribute to the care of our patients.

Historically, our group was founded by Dr. Dennis V. Razis and became the first private Oncology Department in Greece. The group was taken over in the last few years by his daughter, Dr. Evangelia Razis, who continues the founder’s pioneering activity until today.

The aim of our group is to offer modern diagnostic and therapeutic medical services, and continuous comprehensive support for oncology patients and their families.

Our doctors dedicate much of their time to remaining current with the latest trends and are actively involved in various research programs and clinical studies, thus giving our patients access to innovative treatments. They also have an active presence at many conferences and publications in international high impact factor journals. Additionally, our doctors collaborate with prominent international centers and can arrange a mail review of a patient’s record when necessary.

• W.Eiermann, J.Bergh, F.Cardoso, P.Conte, J.Crown, N.J.Curtin, J.Gligorov, B.Gusterson, H.Joensuu, B.K.Linderholm, M.Martin, F.Penault-llorca, B.C.Pestalozzi, E.Razis, C.Sotiriou, S.Tjulandin, G.Viale. Triple Negative Breast Cancer: Proposals for a Pragmatic Definition and Implications for Patient Management and Trial Design. Breast. 2012 Feb; 21(1):20-26.

• E.Razis, K.T.Kalogeras, V.Kotoula, A.Eleftheraki, N.Nikitas, R.Kronenwett, E.Timotheadou, C.Christodoulou, D.Pectasides, H.Gogas, R.Wirtz, T.Makatsoris, D.Bafaloukos, G.Aravantinos, D.Televantou, N.Pavlidis, G.Fountzilas. Improved outcome of high-risk early HER2-positive breast cancer with high CXCL13/CXCR5 mRNA expression. Clinical Breast Cancer, 2012; 12[3]: 183-193.

• E.Razis, P.Nomikos. One More Reason why we Should Treat Unresectable Gliomas. Forum of Clinical Oncology. Editorial. Vol.3, No.3, 2012.

• E.Razis. On the Role of Clinical Practice Guidelines in Oncology. Forum of Clinical Oncology, Editorial.Vol.3, No.3, 2012.

• O.Nikolatou-Galitis, D.Bafaloukos, E.Razis, E.Papadopoulou, H.Linardou, I.Grossi, E.Vardas, A,C,Migliorati. Jaw Osteonecrosis Associated with Medication: Report of two cases addressing unresolved clinical research questions. MOJ;2012:1;45-51.

• G.Rigakos, E.Razis. BRCAness: Finding the Achilles Heel in Ovarian Cancer. The Oncologist 2012;17:1-7.

• F.Stavridi, G.Rigakos, E.Razis. Newer therapeutic agents for urogenital system tumors. Journal of Medical Annals(Hygeia Hospital Monthly Edition), 2012; 16(3): 791-795.

• S.Murray, V.Karavasilis, M.Bobos, E.Razis, S.Papadopoulos, C.Christodoulou, P.Kosmidis, G.Fountzilas. Molecular Predictors of Response to Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer. J Exp Clin Cancer Res. 2012 Sep 19;31(1):77.

• G.Fountzilas, V.Kotoula, D.Pectasides, G.Kouvatseas, E.Timotheadou, M.Bobos, X.Mavropoulou, C.Papadimitriou, E.Vrettou, G.Raptou, A.Koutras, E.Razis, D.Bafaloukos, E.Samantas, G.Pentheroudakis, D.V.Skarlos. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One. 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256.

• G.Pentheroudakis, V.Kotoula, W.DeRoock, G.Kouvatseas, P.Papakostas, T.Makatsoris, D.Papamichael, I.Xanthakis, J.Sgouros, D.Televantou, G.Kafiri, A.C.Tsamandas, E.Razis, E.Galani, D.Bafaloukos, I.Efstratiou, I.Bompolaki, D.Pectasides, N.Pavlidis, S.Tejpar, G.Fountzilas. Biomarkers of benefit from Cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer. 2013 Feb 2; 13:49. doi: 10.1186/1471-2407-13-49. PubMed PMID: 23374602; PubMed Central PMCID: PMC3599697.

• A.Strimpakos, G.Pentheroudakis, V.Kotoula, W.De Roock, G.Kouvatseas, P.Papakostas, T.Makatsoris, A.Zizi-Sermpetzoglou, A.Kominea, D.Televantou, E.Razis, E.Galani, D.Pectasides, S.Tejpar, K.Syrigos, G.Fountzilas. The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17. PubMed PMID: 24050852

• O.Nikolatou-Galitis, E.Razis, D.Galiti, E.Vardas, F.Tzerbos, S.Labropoulos. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib – A case report with clinical implications, FCO, 2013; 4:4:29-33

• E.Razis, G.Pentheroudakis, G.Rigakos, M.Bobos, G.Kouvatseas, O.Tzaida, T.Makatsoris, P.Papakostas, M.Bai, A.Goussia, E.Samantas, D.Papamichael, O.Romanidou, I.Efstratiou, E.Tsolaki, A.Psyrri, W.De Roock, D.Bafaloukos, G.Klouvas, S.Tejpar, K.T. Kalogeras, D.Pectasides, G.Fountzilas. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with wt-KRAS metastatic colorectal cancer treated with Cetuximab. Journal of Cancer Research and Clinical Oncology. 2014 Mar, doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.

• K.Pavlakis, M.Bobos, A.Batistatou, V.Kotoula, A.Eleftheraki, A.Stofas, E.Timotheadou, G.Pentheroudakis, A.Psyrri, A.Koutras, D.Pectasides, P.Papakostas, E.Razis, K.Kalogeras, G.Fountzilas, C.Christodoulou; Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece. p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab. Pathology & Oncology Research. DOI10.1007/s12253-014-9818-2.

• G.Pentheroudakis, V.Kotoula, E.Fountzilas, G.Kouvatseas, G.Basdanis, I.Xanthakis, T.Makatsoris, E.Charalambous, D.Papamichael, E.Samantas, P.Papakostas, D.Bafaloukos, E.Razis, C.Christodoulou, I.Varthalitis, N.Pavlidis, G.Fountzilas. A Study Of Gene Expression Markers For Predictive Significance For Bevacizumab Benefit In Patients With Metastatic Colon Cancer: A Translational Research Study Of The Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111.
Contact usContact us

3rd Floor
Office 57, 59, 60, 61

+30 210 686 7165 
+30 210 686 7071

+30 210 6867175


Medical Team